Medicamen Biotech Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Medicamen Biotech's Board approved the consolidated financial results for the quarter ending June 30, 2025, and the draft Annual Report for FY 2024-25. Key leadership changes include the appointment of Mr. Ashwani Kumar Sharma as Executive Director and Mr. Sham Goel and Mr. Shaival Saurabh as Independent Directors, each for a five-year term. The company also proposed a final dividend of Re. 1 per equity share (10%) for FY 2024-25, pending shareholder approval. The 32nd Annual General Meeting is scheduled for September 26, 2025, via video conference.